You want to be a CBO? Four tips to set you on your way

Most of the titles in a biotech C-suite are generally self-explanatory. The Chief Technical and Manufacturing Officer runs operations in CMC and analytics. The Chief Financial Officer handles financial strategy and investor relations. The Chief Commercial Officer prepares for bringing investigational therapies to market. Then there’s the title I hold: Chief Business Officer (CBO). This […]

Negotiating 101: Gaining leverage – and using it wisely

In a recent blog post, I walked through my tips for reading your adversaries’ body language while maintaining your own poker face throughout negotiations. In this second post, I’ll share practical tactics for gaining leverage and using it wisely. Women of biotech, there’s also a special section for you – so read on! Be prepared […]

A recipe for managing data disclosure successfully with academic partners: A public gene therapy company perspective

When AVROBIO went public in June 2018, I found myself on the steep end of an unexpected but interesting learning curve regarding data disclosure. I had spent years leading Shire’s business development team, so I was well-versed in the regulatory requirements for public companies. However, I suddenly had to reckon with the complexities that ensued […]

Why reputation is more important than ever for biotech companies … and what you can do about it

“It takes twenty years to build a reputation, and five minutes to ruin it,” Warren Buffett said, and added “If you think about that, you’ll do things differently.” In biotech, a strong reputation is difficult to build, is even harder to establish quickly, and can be easily tarnished. So, what’s the landscape and what should […]